Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy (Q50796572)

19 March 2018

http://europepmc.org/abstract/MED/24966003

title

Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy (English)

1 reference

19 March 2018

http://europepmc.org/abstract/MED/24966003

author

Giuseppe V Masucci

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24966003%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Yago Pico de Coaña

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24966003%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Johan Hansson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24966003%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Rolf Kiessling

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24966003%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

publication date

26 June 2014

1 reference

19 March 2018

http://europepmc.org/abstract/MED/24966003

published in

Cancer Immunology, Immunotherapy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24966003%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

63

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24966003%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24966003%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

977-983

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24966003%20AND%20SRC:MED&resulttype=core&format=json

T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression

10 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

A new member of the immunoglobulin superfamily--CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

CTLA-4 is a second receptor for the B cell activation antigen B7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

A molecular perspective of CTLA-4 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Inhibition of IgG1 and IgE production by stimulation of the B cell CTLA-4 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Expression of CTLA-4 by human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Model predicting survival in stage I melanoma based on tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Adoptive-cell-transfer therapy for the treatment of patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

CTLA-4 control over Foxp3+ regulatory T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Biomarkers on melanoma patient T cells associated with ipilimumab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

The terminology issue for myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

On the armament and appearances of human myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Vemurafenib reverses immunosuppression by myeloid derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1570-7